FDA awards orphan designation to Patrys' cancer candidate

11/6/2013 | ProactiveInvestors.co.au (Australia)

The FDA granted orphan-drug status to Patrys' lead cancer candidate PAT-SM6. Patrys said the drug binds to more than 90% of tumors they have screened, regardless of the type and stage of cancer, or patients' gender and age. PAT-SM6 received a similar designation in Europe.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA